Business, energy, technology, markets and global industry news from Business News Today

n-Lorem Foundation

PharmaDeviceNews n-Lorem Foundation
BioMarin and n-Lorem Foundation are advancing early research into a potential antisense medicine targeting the RNU4-2 variant associated with ReNU syndrome, a newly identified rare neurodevelopmental disorder. Representative image.
Pharma & Biotech

How BioMarin and n-Lorem plan to develop an antisense therapy for ReNU syndrome

BioMarin and n-Lorem launch a preclinical antisense program targeting the RNU4-2 variant behind most ReNU syndrome cases.

Read More